Literature DB >> 34107545

Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers.

Antonio Gil-Gómez1,2, Paola Brescia3, Maria Rescigno3, Manuel Romero-Gómez1,2,4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a systemic, dynamic, heterogeneous, and multiaxis entity, the pathogenesis of which is still uncertain. The gut-liver axis is regulated and stabilized by a complex network encompassing a metabolic, immune, and neuroendocrine cross-talk between the gut, the microbiota, and the liver. Changes in the gut-liver axis affect the metabolism of lipids and carbohydrates in the hepatocytes, and they impact the balance of inflammatory mediators and cause metabolic deregulation, promoting NAFLD and its progression to nonalcoholic steatohepatitis. Moreover, the microbiota and its metabolites can play direct and indirect roles in gut barrier function and fibrosis development. In this review, we will highlight findings from the recent literature focusing on the gut-liver axis and its relation to NAFLD. Finally, we will discuss the impact of technical issues, design bias, and other limitations on current knowledge of the gut microbiota in the context of NAFLD. Thieme. All rights reserved.

Entities:  

Year:  2021        PMID: 34107545     DOI: 10.1055/s-0041-1723752

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  2 in total

1.  Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids.

Authors:  Jie Jian; Mei-Tong Nie; Baoyu Xiang; Hui Qian; Chuan Yin; Xin Zhang; Menghui Zhang; Xuan Zhu; Wei-Fen Xie
Journal:  Front Pharmacol       Date:  2022-04-04       Impact factor: 5.988

Review 2.  Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies.

Authors:  Ángela Rojas; María Rosario García-Lozano; Antonio Gil-Gómez; Manuel Romero-Gómez; Javier Ampuero
Journal:  J Clin Transl Hepatol       Date:  2022-01-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.